Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

COALIZAO ACTION
 
NCT04394377
RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive 50%
COALIZAO ACTION
 
NCT04394377
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID 19 hospitalizedsome concern
311/304 inconclusive 50%

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%

COVID-19 severe or critically meta-analysis

COVID-PACT RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
191/191 suggested -8%
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).